Literature DB >> 11516200

Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.

A T Mancino1, V S Klimberg, M Yamamoto, S C Manolagas, E Abe.   

Abstract

BACKGROUND: Breast cancer metastasis to bone causes resorption of the mineralized matrix by osteoclasts. Macrophage colony stimulating factor (M-CSF)and receptor activator of the NF-kappaB ligand (RANKL) are produced by stromal cells and are essential for osteoclast formation. The human breast cancer cell line, MDA-MB-231, reliably forms bone metastases in a murine model and stimulates osteoclast formation in culture. We hypothesized that MDA-MB-231 stimulates osteoclast formation through secretion of M-CSF and/or RANKL.
MATERIALS AND METHODS: We cocultured MDA-MB-231 and a bone marrow derived cell line, UAMS-33, and evaluated the expression of M-CSF and RANKL mRNA. Osteoclast formation was assessed using these cells added to hematopoietic cell cultures.
RESULTS: MDA-MB-231 exhibited constitutive expression of M-CSF mRNA. As expected, addition of recombinant M-CSF (30 ng/ml) and RANKL (30 ng/ml) to hematopoietic osteoclast precursors supported osteoclast formation, while the addition of soluble RANKL alone or MDA-231 without added RANKL did not. Notably, coculture of MDA-231 with hematopoietic cells and added soluble RANKL stimulated significant osteoclast formation, indicating that MDA-231 served as an effective source for M-CSF. MDA-231 did not express RANKL. However, when cocultured with the murine bone marrow stromal cell line UAMS-33, RANKL expression was significantly increased in the latter cells. MDA-231 also stimulated osteoclast formation in coculture with UAMS-33 and hematopoietic cells.
CONCLUSIONS: We conclude that MDA-MB-231 increases osteoclast formation by secreting adequate amounts of M-CSF protein and enhancing the expression of RANKL by stromal support cells. The ability to stimulate osteoclasts may explain the ability to metastasize to bone. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11516200     DOI: 10.1006/jsre.2001.6204

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  31 in total

Review 1.  The macrophage growth factor CSF-1 in mammary gland development and tumor progression.

Authors:  Elaine Y Lin; Valerie Gouon-Evans; Andrew V Nguyen; Jeffrey W Pollard
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

2.  Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation.

Authors:  Kader Yagiz; Susan R Rittling
Journal:  Exp Cell Res       Date:  2009-05-08       Impact factor: 3.905

3.  Breast cancer at bone metastatic sites: recent discoveries and treatment targets.

Authors:  Osama Hussein; Svetlana V Komarova
Journal:  J Cell Commun Signal       Date:  2011-01-19       Impact factor: 5.782

Review 4.  Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.

Authors:  Prashanth Peddi; Maria A Lopez-Olivo; Gregory F Pratt; Maria E Suarez-Almazor
Journal:  Cancer Treat Rev       Date:  2012-08-13       Impact factor: 12.111

5.  The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft.

Authors:  J A Kiefer; R L Vessella; J E Quinn; A M Odman; J Zhang; E T Keller; P J Kostenuik; C R Dunstan; E Corey
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

6.  Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.

Authors:  Jude R Canon; Martine Roudier; Rebecca Bryant; Sean Morony; Marina Stolina; Paul J Kostenuik; William C Dougall
Journal:  Clin Exp Metastasis       Date:  2007-12-05       Impact factor: 5.150

7.  SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

Authors:  Lesley J Murray; Tinya J Abrams; Kelly R Long; Theresa J Ngai; Lisa M Olson; Weiru Hong; Paul K Keast; Jacqueline A Brassard; Anne Marie O'Farrell; Julie M Cherrington; Nancy K Pryer
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Autocrine inhibition of the c-fms proto-oncogene reduces breast cancer bone metastasis assessed with in vivo dual-modality imaging.

Authors:  Justin J Jeffery; Katie Lux; John S Vogel; Wynetta D Herrera; Stephen Greco; Ho-Hyung Woo; Nisreen AbuShahin; Mark D Pagel; Setsuko K Chambers
Journal:  Exp Biol Med (Maywood)       Date:  2014-03-05

9.  Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis.

Authors:  Amy Tomita; Tatsuhiko Kasaoka; Takashi Inui; Minako Toyoshima; Hiroko Nishiyama; Hiromasa Saiki; Haruo Iguchi; Motowo Nakajima
Journal:  Clin Exp Metastasis       Date:  2008-02-27       Impact factor: 5.150

10.  Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.

Authors:  T Ohshiba; C Miyaura; M Inada; A Ito
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.